Management of Type 2 Diabetes (NICE Guideline)

Summary of NICE guidance on treatment of type 2 diabetes.

NICE recommends that care be tailored to the needs and circumstances of the individual patient, taking into account their personal preferences, comorbidities, risks from polypharmacy, and ability to benefit from long-term interventions.

 Download a pdf version of the above chart.

Adapted from: NICE Clinical Guideline 28 (December 2015; updated May 2017) - Type 2 diabetes in adults: management.

KEYWORDS: Canagliflozin | Dapagliflozin | DPP4 inhibitor | Empagliflozin | Exenatide | Glitazones | GLP-1 agonists | Insulin detemir | Insulin glargine | Insulin secretagogues | Linagliptin | Liraglutide | Lixisenatide | Metformin | Monitoring | Pioglitazone | Repaglinide | Saxagliptin | SGLT2 inhibitors | Sitagliptin | Sulfonylureas | Vildagliptin

Read these next

Rapid-acting insulin aspart launched

Rapid-acting insulin aspart launched

Fiasp is a formulation of insulin aspart that includes...

SGLT2 inhibitors endorsed for NHS use as monotherapies

SGLT2 inhibitors endorsed for NHS use as monotherapies

Canagliflozin, dapagliflozin and empagliflozin have...

Foot care reminder for canagliflozin prescribing

Foot care reminder for canagliflozin prescribing

Healthcare professionals have been reminded of the...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more